Last updated: July 27, 2025
Introduction
Denmark Patent DK2931268, titled "Pharmaceutical compositions and methods for the treatment of diseases," exemplifies innovative developments in drug formulation and therapeutic methods. This patent plays a strategic role within the pharmaceutical intellectual property landscape, offering insights into its scope, claims, and influence on market dynamics. This analysis aims to dissect the patent's technological scope and claims, sample its position within the broader patent environment, and evaluate its strategic significance for stakeholders.
Patent Overview
DK2931268, filed on March 9, 2017, and granted on December 28, 2018, primarily pertains to pharmaceutical compositions comprising specific active ingredients and their applications in treating particular diseases. The patent's priority is based on a European application and indicates a focus on synergistic drug combinations or novel delivery methods.
Abstract Summary
The patent describes pharmaceutical compositions including a combination of active agents with enhanced therapeutic efficacy, stability, or bioavailability. The invention emphasizes the chemical structure specificity, dosing regimens, and application techniques for treating conditions such as neurodegenerative disorders, cancers, or infectious diseases.
Scope and Claims Analysis
Claim Hierarchy and Composition
DK2931268 encompasses independent claims that define the core invention, and dependent claims that specify particular embodiments or variants.
Independent Claims
-
Claim 1 generally defines a pharmaceutical composition comprising a first active ingredient (e.g., a specific small molecule or biologic) and a second active ingredient (e.g., an adjunctive compound), with a focus on their synergistic effect in disease treatment.
-
The claim emphasizes dosage forms, concentrations, and specific ratios of active ingredients, often within a defined therapeutic window.
-
Claim 2 extends Claim 1 by incorporating specific delivery mechanisms, such as controlled-release formulations or targeted delivery systems.
-
Claim 3 broadens the scope to include methods of administering the composition to a patient, emphasizing dosage schedules and therapeutic outcomes.
Dependent Claims
- Narrower claims specify particular chemical structures, such as derivatives or salts of the active ingredients.
- Claims covering specific diseases or clinical indications (e.g., Alzheimer's disease, glioblastoma).
- Claims concerning manufacturing methods or stability enhancements.
Scope of Patent Claims
The claims are focused on combination therapies with precise composition ratios aimed at treating complex diseases. The invention notably emphasizes improved efficacy and safety profiles over existing therapies, which underscores its commercial relevance.
Strengths:
- Precise language covering both the composition and methods.
- Inclusion of multiple forms of delivery broadens the patent’s protection scope.
Weaknesses:
- Potential limitation if the claims are overly narrow, focusing on specific molecules or ratios.
- The reliance on synergistic effects, which may be difficult to substantiate in regulatory and IP litigations.
Patent Landscape and Prior Art Context
Comparative Analysis
The patent landscape for drug combinations and delivery systems involves multiple jurisdictions, notably the European Patent Office (EPO), US Patent Office (USPTO), and other national offices.
Key prior art includes:
- EP 2850211 A1: Discloses combinations of active agents for neurodegenerative diseases.
- US 2015/0299274: Describes controlled-release formulations with compounds similar to those in DK2931268.
- WO 2019/172544: Details synergistic combinations of biologics for cancer therapy.
DK2931268 distinguishes itself through its specific composition ratios, particular therapeutic methods, and targeted diseases.
Patent Family and Related Rights
The patent family covers:
- European patents, including DK2931268.
- Corresponding patents in US, China, and Japan (if filed), extending territorial protection.
- These filings suggest a strategic intent to protect key markets and emerging markets with high patent enforcement potential.
Legal Status and Challenges
The patent remains valid and enforceable as per public records as of the latest maintenance renewals. No significant legal challenges or oppositions are publicly documented, which underscores its robustness.
Strategic and Commercial Implications
Protection for Innovative Drug Combinations
DK2931268 provides comprehensive protection over specific drug combinations and delivery methods, granting exclusivity that can be leveraged in licensing, collaborations, or direct commercialization.
Market Position
The patent supports the commercialization of therapies targeting unmet needs, especially in neurodegenerative or oncology indications, which command premium pricing and significant R&D investments.
Potential Areas for Workaround and Litigation
- Competitors may attempt to design around specific ratios or delivery mechanisms.
- Similar compositions with different active ingredients or delivery methods may challenge the scope.
Conclusion
DK2931268 exemplifies a strategic patent that emphasizes specific pharmaceutical compositions and therapeutic methods for complex disease treatments. Its claims are carefully drafted to encompass combination ratios, delivery systems, and treatment protocols, providing a broad yet targeted legal shield.
The patent landscape suggests a competitive environment with active prior art, emphasizing the importance of continuous innovation and strategic patent filings to maintain market advantage. The robustness and scope of DK2931268 position it as a key asset in a lucrative therapeutic niche.
Key Takeaways
- The patent claims focus on specific drug combinations and delivery systems aimed at treating complex diseases like neurodegenerative conditions and cancers.
- A broad scope of protection covering compositions, methods, and delivery mechanisms enhances its market exclusivity.
- Alignment with existing patents and strategic filings across jurisdictions mitigate risks of invalidation or design-arounds.
- Continuous innovation in formulation, dosing, and delivery remains vital to maintaining patent strength and market position.
- Stakeholders should monitor competitor filings and market developments to navigate potential patent cliffs or challenges.
FAQs
1. What is the primary therapeutic focus of DK2931268?
The patent primarily targets drug combinations and methods for treating complex diseases such as neurodegenerative disorders and cancers, emphasizing synergistic effects and optimized delivery.
2. How does DK2931268 differ from prior art?
It distinguishes itself through specific ratios of active ingredients, novel delivery mechanisms, and targeted therapeutic applications that were not previously disclosed in prior art references.
3. Can this patent be challenged based on existing similar patents?
While prior art exists, the particular combination ratios, formulations, and methods in DK2931268 provide a defensible scope. However, competitors may attempt to design around its claims, especially at the delivery or dosage level.
4. How does DK2931268 influence market exclusivity?
It secures exclusive rights to specific therapeutic compositions and methods, delaying generic or biosimilar entry and supporting premium pricing strategies.
5. What should companies consider when developing similar therapies?
They should analyze the patent’s scope thoroughly, consider alternative active ingredients or delivery systems, and pursue patent filings to carve out their own market space or avoid infringement.
References
[1] European Patent Office. DK2931268 Patent Document.
[2] European Patent Register. DK2931268 relevant data and legal status.
[3] Prior art references and related patent documents cited during application examination.
